California distributes over 120,000 low-cost insulin glargine packs as Novo Nordisk CEO warns investors on obesity drug differentiation
California's state health program has been distributing a low-cost insulin glargine product, more than 120,000 five-pen packs since its launch seven months ago.
Each pack is priced at $55, which is substantially lower than typical retail prices, aiming to improve affordability for patients with diabetes.
Meanwhile, Novo Nordisk CEO Mike Doustdar said investors are undervaluing the market need for differentiated obesity therapies, noting that oral options could expand treatment choices.
The comments highlight two parallel trends in pharma: state-driven pricing initiatives for essential medicines and growing interest in novel obesity drug formats that could reshape market dynamics.
This writeup was produced by pharmadog from original reporting by STAT.
Original headline: “STAT+: Pharmalittle: We’re reading about California insulin sales, a Moderna patent battle, and more”
read at STAT ↗
comments(0)
5-min edit window · permanent after that